Not applicableApproved For MarketingNCT05172700
What this trial is testing
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Lymphocytic, SmallLymphoma, Mantle-Cell+2 more
Loxo Oncology, Inc.